Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Lipitor Patent Claiming Crystalline Atorvastatin Is Valid, PTO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The Public Patent Foundation nevertheless asserts victory, saying Pfizer was forced to narrow the claims for the '156 patent.

You may also be interested in...



Pfizer Lipitor Patent Found Invalid By Patent & Trademark Office

PTO rejects claims in patent ’156, covering crystalline form of atorvastatin, after finding product is covered in two earlier patents. Pfizer says decision is “preliminary” and plans to respond “in due course.”

Expanded Lung Cancer Claim For Lilly’s Cyramza Faces US FDA Scrutiny

Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.

Steba’s Tookad: US FDA Panel To Weigh Novel Endpoints, Missing Data And Toxicities

Sponsor seeks accelerated approval for low-risk, early-stage prostate cancer based on a trial that met its coprimary endpoints, but agency says interpretation of those results is complicated by novelty of the outcomes, data quality issues and increase in genitourinary adverse events.

Topics

UsernamePublicRestriction

Register

PS061323

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel